Purines syntheses

Purine Synthesis Purine Salvage Deoxynucleotides Purine Degradation 

Function To provide purines (A and G) for energy metabolism and for DNA-RNA synthesis. 

Connections To folate metabolism and one-carbon metabolism in de novo synthesis. 

To deoxyribonucleotides through ribonucleotide reductase. Regulation Availability of PRPP. 

Activity of the enzyme catalyzing the formation of the 5-phos-phoribosyl-1-amine from PRPP is inhibited by purines. Synthesis of GMP requires ATP. 

---

Formylation of folate (3) or hydrolysis of 5,10 — CH+ — folate (9) gives (6R,3)-5-formyltetrahydrofohc acid (6) (5-HCO-H folate) (55). On the other hand, (63)-5-HCO-H4 folate is obtained by selective crystaUi2ation in the form of its calcium salt from the diastereomeric mixture of (63, R)-5-HC0-H4 folate (56). 10-Formyltetrahydrofohc acid (7) is a coen2yme in purine synthesis which is synthesi2ed by hydrolysis of 5,10 — CH+ — folate (9) or by hydrogenation of lO-CHO-folate (57). 

Pyrimidine-5-carboxamide, 4-amino-purine synthesis from, 5, 582 Pyrimidine-5-carboxamide, 4-amino- N- pheny synthesis, 3, 122 Pyrimidinecarboxamides Curtius degradation, 3, 82 dehydration, 3, 82 Hofmann degradation, 3, 82 hydrolysis, 3, 81 reactions, 3, 81 synthesis, 3, 127 Pyrimidinecarboxamides, thio-synthesis, 3, 128... 

Tetrazolo[l,5-c]pyrimidine, 8-amino-7-chloro-purine synthesis from, 5, 591 Tetrazolopyrimidines... 

Thiazolo[5,4-d]pyrimidine, 2,5,7-trichloro-nucleopfulic substitution, 6, 686 Thiazolo[3,2-a]pyrimidine-5,7-diones IR spectra, 6, 672 Thiazolopyrimidines synthesis, 5, 572, 574, 578 Thiazolopyrimidines, amino-purine synthesis from, 5, 591 Thi azolo[3,2-ajpyrimidines synthesis... 

Substitution of more complex acids for formic acid in the last step of the purine synthesis will afford intermediates substituted on the imidazole carbon atom. Thus, condensation of diaminouracyl, 12, with phenylacetic acid gives the benzylated... 

Methotrexate (MTX, chemical structure shown in Fig. 1.) competitively inhibits the dehyrofolate reductase, an enzyme that plays an essential role in purine synthesis. The dehydrofolate reductase regenerates reduced folates when thymidine monophosphate is formed from deoxyuridine monophosphate. Without reduced folates cells are unable to synthesize thymine. Administration of N-5 tetrahydrofolate or N-5 formyl-tetrahydrofolate (folinic acid) can bypass this block and rescue cells from methotrexate activity by serving as antidote. 

Inosine monophosphate dehydrogenase (EVDPDH) is a key enzyme of purine nucleotide biosynthesis. Purine synthesis in lymphocytes exclusively depends on the de novo synthesis, whereas other cells can generate purines via the so-called salvage pathway. Therefore, IMPDH inhibitors preferentially suppress DNA synthesis in activated lymphocytes. 

The carbons added in reactions 4 and 5 of Figure 34-2 are contributed by derivatives of tetrahydrofolate. Purine deficiency states, which are rare in humans, generally reflect a deficiency of folic acid. Compounds that inhibit formation of tetrahydrofolates and therefore block purine synthesis have been used in cancer chemotherapy. Inhibitory compounds and the reactions they inhibit include azaserine (reaction 5, Figure 34—2), diazanorleucine (reaction 2), 6-mercaptopurine (reactions 13 and 14), and mycophenofic acid (reaction 14). 

Mycophenolate mofetil was approved by the FDA in 1995, and enteric-coated mycophenolic acid was approved in 2004. Both agents are considered to be adjunctive immunosuppressants. Mycophenolic acid acts by inhibiting inosine monophosphate deydrogenase, a vital enzyme in the de novo pathway of purine synthesis. Inhibition of this enzyme prevents the proliferation of most cells that are dependent on the de novo pathway for purine synthesis, including T cells.7,11,26-28... 

Mercaptopurine (6-MP) is an oral purine analog that is converted to a ribonucleotide to inhibit purine synthesis. Mercaptopurine is converted into thiopurine nucleotides, which are catabolized by thiopurine S-methyltransferase (TPMT), which is subject to genetic polymorphisms and may cause severe myelosuppression. TPMT status may be assessed prior to therapy to reduce drug-induced morbidity and the costs of hospitalizations for neutropenic events. Mercaptopurine is poorly absorbed, with a time to peak concentration of 1 to 2 hours after an oral dose. The half-life is 21 minutes in pediatric patients and 47 minutes in adults. Mercaptopurine is used in the treatment of acute lymphocytic leukemia and chronic myelogenous leukemia. Significant side effects include myelosuppression, mild nausea, skin rash, and cholestasis. When allopurinol is used in combination with 6-MP, the dose of 6-MP must be reduced by 66% to 75% of the usual dose because allopurinol blocks the metabolism of 6-MP. 

Folates carry one-carbon groups in transfer reactions required for purine and thymidylic acid synthesis. Dihydrofolate reductase is the enzyme responsible for supplying reduced folates intracellularly for thymidylate and purine synthesis. 

Folic acid antagonist inhibits dihydrofolate reductase (DHFR) blocks reduction of folate to tetrahydrofolate inhibits de novo purine synthesis results in arrest of DNA, RNA, and protein synthesis... 

A more recent, extended study of purine synthesis via polymerisation of ammonium cyanide, described at the beginning of this section, showed that the yield of adenine from the non-hydrolyzed solution was only slightly temperature dependent. Shorter hydrolysis times for the insoluble polymerisation products led to higher adenine yields. When the solution is hydrolyzed at pH 8, the adenine yield is comparable to the value of 0.1% found for acidic hydrolysis (a model for the primeval ocean ). Increasing the hydrolysis time has no effect on the adenine yield because of its greater stability at pH 8. Hydrolysis of the black NH4CN polymer under acidic or neutral conditions results in an adenine yield of about 0.05% (Borquez et al., 2005). 

A novel approach to purine synthesis involves the use of ADC compounds as a source of one nitrogen atom in the five-membered ring.148 150 Treatment of 6-amino-l,3-dimethyluracil (94, R = H) with DEAZD gives the 5-substitution product (95, R = H). The N—N bond is cleaved by Raney nickel or formic acid, and ring closure to 1,3-dimethyluric acid is simply effected by heating.148 Whether the initial adduct is formed by a substitution... 

---